Under the license agreement, Myung In Pharm will contribute 10% of patients to Newron’s Phase III trial and cover related costs. They will also bear a percentage of global development costs and handle all regulatory, marketing, and commercialization costs for evenamide in South Korea. Newron will receive upfront and milestone payments, plus royalties on net sales.

“We are thrilled to partner with Myung In Pharm in this important clinical trial and to grant them the rights to develop, manufacture and commercialize evenamide in South Korea,” said Stefan Weber, CEO of Newron. “Their strong expertise in CNS therapies and their clinical infrastructure will be instrumental in advancing the development of evenamide. This collaboration underscores our shared commitment to transforming the treatment landscape for patients with unmet needs."

The Phase III trial, starting in H1 2025, will compare evenamide to placebo in at least 600 patients with TRS. Newron will oversee the trial, while Myung In Pharm will enroll patients in South Korea and support monitoring and data collection. Newron is also pursuing further development opportunities for evenamide in other territories, including a recent agreement with EA Pharma for Japan and other Asian regions.

“Newron’s innovative approach aligns with our commitment to improving patient outcomes in the CNS area, and we believe our participation will make a significant contribution to the success of the study," added Hang Myung Lee, Chairman of Myung In Pharm. "Furthermore, we are honored to have received the license to commercialize evenamide in South Korea. This partnership presents a valuable opportunity for us to bring a new treatment option to patients in South Korea, a key market for Myung In Pharm. We look forward to working closely with the Newron team to bring this promising therapeutic to the forefront of clinical development and expand its impact in South Korea.”